Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 16
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Title
Phase
Protocol IDs
Trastuzumab With or Without Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Phase III
SWS-SAKK-22/99
EU-99028, NCT00004935
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
Phase III
A6181094
NCT00373256
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
Phase III
NSABP-B-40
NCT00408408
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Phase III
BO20231
NCT00391092
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Phase III
ECOG-E5103
E5103, NCT00433511
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Phase III
A6181114
NCT00428220
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
Phase III
A6181099
NCT00435409
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Phase III
MO19391
NCT00448591
First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase III
ECOG-E1105
E1105, NCT00520975
BEVACIZUMAB + LETROZOL vs LETROZOL as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer
Phase III
GEICAM/2006-11
NÂș EudraCT: 2007-002841-19, NCT00545077
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute